Research Topics
| C A LeissingerSummaryAffiliation: Tulane University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitorsCindy A Leissinger
Louisiana Center for Bleeding and Clotting Disorders, Tulane University Medical Center, New Orleans, Louisiana 70112, USA
Am J Hematol 87:S23-6. 2012..Over the last seven decades, major strides have been made in inhibitor treatment. This article focuses on the seminal clinical observations and studies that provided the foundation for these advances in hemophilia care...
Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac seraScott A Tenenbaum
Department of Biomedical Sciences, Ge NY Sis Center for Excellence in Cancer Genomics, University at Albany SUNY, Albany, NY, USA
Virol J 2:65. 2005....- Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitorsCindy Leissinger
Louisiana Center for Bleeding and Clotting Disorders, Tulane University, New Orleans, LA, USA
N Engl J Med 365:1684-92. 2011..Effective strategies to prevent bleeding in such patients have not yet been established... 
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literatureCindy A Leissinger
The Louisiana Center for Bleeding and Clotting Disorders, Tulane University School of Medicine, New Orleans, Louisiana 70221 2699, USA
Am J Hematol 83:137-43. 2008..Evidence-based treatment guidelines are needed to optimize the use of PCCs for warfarin reversal...- Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitorsC A Leissinger
Section of Hematology Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA
Haemophilia 13:249-55. 2007..This case series demonstrates that routine aPCC administration may be used safely and effectively to reduce the occurrence of bleeding episodes and to maintain or improve clinical joint status in some patients... - Prophylaxis in haemophilia patients with inhibitorsC A Leissinger
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
Haemophilia 12:67-72; discussion 72-3. 2006..This article will review the published data on the use of bypassing agents in the prevention of bleeding, and will discuss ongoing clinical prophylaxis trials in inhibitor patients... - Inhibitor development in patients with hemophilia: an overviewCindy A Leissinger
Tulane University, New Orleans, LA 70112, USA
Semin Hematol 43:S1-2. 2006 - Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical directionCindy A Leissinger
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
Am J Hematol 77:187-93. 2004..However, only controlled clinical trials will ultimately demonstrate whether prophylaxis can prevent joint bleeding and damage, and improve quality of life in patients with inhibitors... - Platelet kinetics in immune thrombocytopenic purpura and human immunodeficiency virus thrombocytopeniaC A Leissinger
Tulane University School of Medicine, Section of Hematology and Medical Oncology, New Orleans, Louisiana 70112 2699, USA
Curr Opin Hematol 8:299-305. 2001..For all patients with ITP-like disorders, these studies may also prove helpful in understanding and improving current therapies... - Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAARTR Kruse-Jarres
Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA
Haemophilia 13:707-11. 2007..Such a case serves to augment knowledge gained in animal studies about the immunobiology of FVIII inhibitors... - Diabetes treatments have differential effects on nontraditional cardiovascular risk factorsVivian A Fonseca
Tulane University Health Sciences Center, New Orleans, LA 70112, USA
J Diabetes Complications 20:14-20. 2006..The aim of this study was to determine the effect of basal insulin, alone or with a sensitizer, or a combination of oral agents on nontraditional risk factors for cardiovascular disease (CVD)... - Current management of acquired factor VIII inhibitorsBrian Barnett
Tulane University School of Medicine, New Orleans, Louisiana, USA
Curr Opin Hematol 15:451-5. 2008..Appropriate management requires the urgent treatment of bleeding episodes and prompt institution of immunosuppressive therapy for long-term inhibitor eradication... - Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia populationS du Treil
Tulane University Health Science Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
Haemophilia 13:493-501. 2007.... - Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia BBruce M Ewenstein
Hematology Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Transfusion 42:190-7. 2002..Hemophilia B is an X-linked bleeding disorder that affects approximately 1 in 25,000 males. Therapy for acute bleeding episodes consists of transfusions of plasma-derived (pd-F IX) or recombinant (r-F IX) concentrates...
Research Grants
- Hemostasis Clinical Research Network ProtocolsCindy Leissinger; Fiscal Year: 2007..tulane university critiques ..
- Hemostasis Clinical Research Network ProtocolsCindy Leissinger; Fiscal Year: 2006..The second, short-term protocol, A prospective study of ribavirin for the treatment of HIVassociated immunopathic thrombocytopenic purpura (ITP), was developed to test a novel pharmacologic agent in the management of HIV-ITP. ..